Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

Novo Nordisk (NVO) faces significant challenges ahead of its Q3 2025 earnings report, with consensus estimates at $11.88 billion revenue and $0.77 EPS, and deteriorating 2025/2026 EPS forecasts. Growth for its key GLP-1 drugs, Wegovy and Ozempic, is slowing due to intense competition from Eli Lilly's Mounjaro/Zepbound and the persistence of compounded alternatives, leading NVO to announce 9,000 job cuts and a restructuring aimed at DKK 8 billion in savings. Additionally, potential U.S. government-mandated price cuts for these drugs, as hinted by former President Trump, threaten profitability in its largest market, contributing to NVO's 42.5% year-to-date share underperformance and a Zacks #4 (Sell) rating, suggesting a downside-skewed near-term risk/reward profile for investors.

Analysis

Novo Nordisk (NVO) faces significant headwinds ahead of its Q3 2025 earnings report on November 5th, with consensus estimates at $11.88 billion revenue and $0.77 EPS. Analyst sentiment is strongly negative, evidenced by a Zacks Rank #4 (Sell) and a -11.04% Earnings ESP, indicating a low probability of an earnings beat. Furthermore, 2025 and 2026 EPS forecasts have deteriorated over the past 60 days, falling from $3.84 to $3.67 and $3.97 to $3.91 respectively.

The company's crucial GLP-1 franchise, including Wegovy and Ozempic, is experiencing slower-than-expected U.S. momentum due to intense competition from Eli Lilly's Mounjaro and Zepbound, alongside the persistent market presence of unregulated compounded semaglutide products. This competitive pressure and a July guidance cut prompted NVO to announce a major restructuring in September 2025, including 9,000 job cuts, targeting DKK 8 billion in annual savings by 2026.

External risks, such as potential U.S. government-mandated price reductions for Ozempic and Wegovy, as hinted by former President Trump, pose a serious threat to profitability in NVO's largest market. This regulatory uncertainty, combined with increasing competition from new entrants like Amgen and Viking Therapeutics, has contributed to NVO's 42.5% year-to-date stock underperformance against an industry that grew 4.8%. Despite trading at a forward P/E of 12.79, a discount to the industry's 15.42, the near-term risk/reward profile appears skewed to the downside.

Key Decisions for Investors

• Investors should consider reducing exposure to Novo Nordisk given the confluence of competitive, regulatory, and internal operational challenges impacting near-term growth and profitability.
• Closely monitor upcoming Q3 2025 earnings for further guidance revisions, particularly regarding GLP-1 sales trajectory and the impact of restructuring efforts.
• Evaluate the evolving competitive landscape, especially Eli Lilly's market share gains and new entrants, as well as political developments concerning U.S. drug pricing.